Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Neurotherapeutics ; 18(3): 1980-1994, 2021 07.
Article in English | MEDLINE | ID: mdl-33829411

ABSTRACT

Numerous therapies aimed at driving an effective anti-glioma response have been employed over the last decade; nevertheless, survival outcomes for patients remain dismal. This may be due to the expression of immune-checkpoint ligands such as PD-L1 by glioblastoma (GBM) cells which interact with their respective receptors on tumor-infiltrating effector T cells curtailing the activation of anti-GBM CD8+ T cell-mediated responses. Therefore, a combinatorial regimen to abolish immunosuppression would provide a powerful therapeutic approach against GBM. We developed a peptide ligand (CD200AR-L) that binds an uncharacterized CD200 immune-checkpoint activation receptor (CD200AR). We sought to test the hypothesis that CD200AR-L/CD200AR binding signals via he DAP10&12 pathways through in vitro studies by analyzing transcription, protein, and phosphorylation, and in vivo loss of function studies using inhibitors to select signaling molecules. We report that CD200AR-L/CD200AR binding induces an initial activation of the DAP10&12 pathways followed by a decrease in activity within 30 min, followed by reactivation via a positive feedback loop. Further in vivo studies using DAP10&12KO mice revealed that DAP10, but not DAP12, is required for tumor control. When we combined CD200AR-L with an immune-stimulatory gene therapy, in an intracranial GBM model in vivo, we observed increased median survival, and long-term survivors. These studies are the first to characterize the signaling pathway used by the CD200AR, demonstrating a novel strategy for modulating immune checkpoints for immunotherapy currently being analyzed in a phase I adult trial.


Subject(s)
Antigens, CD/metabolism , Brain Neoplasms/metabolism , Glioma/metabolism , Immune Checkpoint Inhibitors/metabolism , Membrane Glycoproteins/metabolism , Receptors, Immunologic/deficiency , Amino Acid Sequence , Animals , Antigens, CD/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/metabolism , Brain Neoplasms/drug therapy , Brain Neoplasms/genetics , Female , Genetic Therapy/methods , Glioma/drug therapy , Glioma/genetics , Immune Checkpoint Inhibitors/administration & dosage , Membrane Glycoproteins/antagonists & inhibitors , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Structure, Tertiary , Receptors, Immunologic/genetics , Signal Transduction/drug effects , Signal Transduction/physiology , Tumor Microenvironment/drug effects , Tumor Microenvironment/physiology
3.
Mol Cell Biol ; 37(21)2017 Nov 01.
Article in English | MEDLINE | ID: mdl-28760776

ABSTRACT

DNA repair pathways are aberrant in cancer, enabling tumor cells to survive standard therapies-chemotherapy and radiotherapy. Our group previously reported that, upon irradiation, the membrane-bound tyrosine kinase receptor TIE2 translocates into the nucleus and phosphorylates histone H4 at Tyr51, recruiting ABL1 to the DNA repair complexes that participate in the nonhomologous end-joining pathway. However, no specific molecular mechanisms of TIE2 endocytosis have been reported. Here, we show that irradiation or ligand-induced TIE2 trafficking is dependent on caveolin-1, the main component of caveolae. Subcellular fractionation and confocal microscopy demonstrated TIE2/caveolin-1 complexes in the nucleus, and using inhibitor or small interfering RNAs (siRNAs) against caveolin-1 or Tie2 inhibited their trafficking. TIE2 was found in caveolae and directly phosphorylated caveolin-1 at Tyr14 in vitro and in vivo This modification regulated the generation of TIE2/caveolin-1 complexes and was essential for TIE2/caveolin-1 nuclear translocation. Our data further demonstrate that the combination of TIE2 and caveolin-1 inhibitors resulted in significant radiosensitization of malignant glioma cells, which will guide the development of combinatorial treatment with radiotherapy for patients with glioblastoma.


Subject(s)
Caveolae/metabolism , Caveolin 1/metabolism , Cell Nucleus/metabolism , Glioma/metabolism , Receptor, TIE-2/metabolism , Animals , Cell Line, Tumor , Gene Expression Regulation, Neoplastic/radiation effects , HEK293 Cells , HeLa Cells , Human Umbilical Vein Endothelial Cells , Humans , Phosphorylation/radiation effects , Protein Transport/radiation effects , Up-Regulation/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...